Heart drug developer Kardigan has raised $400 million in its initial public offering, according to BioPharma Dive. The deal extends a notable streak for the biotech sector.
With Kardigan's offering, four biotechs in 2026 have now raised at least $400 million in IPO proceeds. That marks the most such large offerings in a single year since 2021, based on BioPharma Dive data.
The IPO market for biotech companies has shown renewed vigor in 2026. The string of big raises suggests improved investor appetite for therapeutic developers, particularly those with advanced clinical programs.
Kardigan focuses on heart disease, an area with significant unmet need. Cardiovascular conditions remain a leading cause of death globally, creating substantial commercial opportunity for effective new treatments.
Larger biotech offerings typically require companies to have late-stage clinical data or approved products. The trend may signal that investors are increasingly willing to back companies with clear regulatory pathways to market.